Literature DB >> 27765741

MRI Brain Volume Measurements in Infantile Neuronal Ceroid Lipofuscinosis.

E H Baker1, S W Levin2, Z Zhang2, A B Mukherjee2.   

Abstract

BACKGROUND AND
PURPOSE: Infantile neuronal ceroid lipofuscinosis is a devastating neurodegenerative storage disease caused by palmitoyl-protein thioesterase 1 deficiency, which impairs degradation of palmitoylated proteins (constituents of ceroid) by lysosomal hydrolases. Consequent lysosomal ceroid accumulation leads to neuronal injury, resulting in rapid neurodegeneration and childhood death. As part of a project studying the treatment benefits of a combination of cysteamine bitartrate and N-acetyl cysteine, we made serial measurements of patients' brain volumes with MR imaging.
MATERIALS AND METHODS: Ten patients with infantile neuronal ceroid lipofuscinosis participating in a treatment/follow-up study underwent brain MR imaging that included high-resolution T1-weighted images. After manual placement of a mask delineating the surface of the brain, a maximum-likelihood classifier was applied to determine total brain volume, further subdivided as cerebrum, cerebellum, brain stem, and thalamus. Patients' brain volumes were compared with those of a healthy population.
RESULTS: Major subdivisions of the brain followed similar trajectories with different timing. The cerebrum demonstrated early, rapid volume loss and may never have been normal postnatally. The thalamus dropped out of the normal range around 6 months of age; the cerebellum, around 2 years of age; and the brain stem, around 3 years of age.
CONCLUSIONS: Rapid cerebral volume loss was expected on the basis of previous qualitative reports. Because our study did not include a nontreatment arm and because progression of brain volumes in infantile neuronal ceroid lipofuscinosis has not been previously quantified, we could not determine whether our intervention had a beneficial effect on brain volumes. However, the level of quantitative detail in this study allows it to serve as a reference for evaluation of future therapeutic interventions.
© 2017 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27765741      PMCID: PMC5309144          DOI: 10.3174/ajnr.A4978

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  23 in total

1.  EEG and evoked potentials in infantile neuronal ceroid-lipofuscinosis.

Authors:  S L Vanhanen; K Sainio; M Lappi; P Santavuori
Journal:  Dev Med Child Neurol       Date:  1997-07       Impact factor: 5.449

2.  Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis.

Authors:  Catherine Kielar; Lucy Maddox; Ellen Bible; Charlie C Pontikis; Shannon L Macauley; Megan A Griffey; Michael Wong; Mark S Sands; Jonathan D Cooper
Journal:  Neurobiol Dis       Date:  2006-10-12       Impact factor: 5.996

Review 3.  Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinoses.

Authors:  Varun Warrier; Mariana Vieira; Sara E Mole
Journal:  Biochim Biophys Acta       Date:  2013-03-28

Review 4.  Genetics of the neuronal ceroid lipofuscinoses (Batten disease).

Authors:  Sara E Mole; Susan L Cotman
Journal:  Biochim Biophys Acta       Date:  2015-05-27

5.  Lysosomal ceroid depletion by drugs: therapeutic implications for a hereditary neurodegenerative disease of childhood.

Authors:  Z Zhang; J D Butler; S W Levin; K E Wisniewski; S S Brooks; A B Mukherjee
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

6.  MRI evaluation of the brain in infantile neuronal ceroid-lipofuscinosis. Part 2: MRI findings in 21 patients.

Authors:  S L Vanhanen; R Raininko; T Autti; P Santavuori
Journal:  J Child Neurol       Date:  1995-11       Impact factor: 1.987

Review 7.  Current state of clinical and morphological features in human NCL.

Authors:  Hans H Goebel; Krystyna E Wisniewski
Journal:  Brain Pathol       Date:  2004-01       Impact factor: 6.508

8.  Batten disease: past, present, and future.

Authors:  J A Rider; D L Rider
Journal:  Am J Med Genet Suppl       Date:  1988

Review 9.  The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction.

Authors:  Frances M Platt; Barry Boland; Aarnoud C van der Spoel
Journal:  J Cell Biol       Date:  2012-11-26       Impact factor: 10.539

10.  Evaluation of disease progression in INCL by MR spectroscopy.

Authors:  Eva H Baker; Sondra W Levin; Zhongjian Zhang; Anil B Mukherjee
Journal:  Ann Clin Transl Neurol       Date:  2015-07-01       Impact factor: 4.511

View more
  6 in total

1.  Fast Progression of Cerebellar Atrophy in PLA2G6-Associated Infantile Neuronal Axonal Dystrophy.

Authors:  Mario Mascalchi; Francesco Mari; Beatrice Berti; Emanuele Bartolini; Matteo Lenge; Andrea Bianchi; Laura Antonucci; Filippo M Santorelli; Barbara Garavaglia; Renzo Guerrini
Journal:  Cerebellum       Date:  2017-06       Impact factor: 3.847

Review 2.  Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis.

Authors:  Konrad Kaminiów; Sylwia Kozak; Justyna Paprocka
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

3.  Expanding the Neuroimaging Phenotype of Neuronal Ceroid Lipofuscinoses.

Authors:  A Biswas; P Krishnan; A Amirabadi; S Blaser; S Mercimek-Andrews; M Shroff
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-27       Impact factor: 3.825

Review 4.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

Review 5.  Neuronal Ceroid Lipofuscinosis: The Multifaceted Approach to the Clinical Issues, an Overview.

Authors:  Alessandro Simonati; Ruth E Williams
Journal:  Front Neurol       Date:  2022-03-11       Impact factor: 4.003

6.  Spinal manifestations of CLN1 disease start during the early postnatal period.

Authors:  H R Nelvagal; J T Dearborn; J R Ostergaard; M S Sands; J D Cooper
Journal:  Neuropathol Appl Neurobiol       Date:  2020-09-07       Impact factor: 8.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.